You are here

Trials

The following are trials implementing Precision Cancer Medicine at The Ohio State University Comprehensive Cancer Center:

ACTIVE

OSU-13053: Precision Cancer Medicine for Advanced Cancer Through High-Throughput Sequencing

OSU-13053: Sub-Study: Body Donation for Cancer Research.

OSU-15030: Novel Molecular Diagnostics for Cancer: Clinical Validation and Discovery  

Targeted Therapies

OSU-14078: Phase II Study of ponatinib for advanced cancers with genomic alterations in fibroblast growth factor receptor (FGFR) and other genomic targets (KIT, PDGFRA, RET, FLT3, ABL1).

OSU-14106: CBGJ398X2204: A Phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy.

OSU-15241: INCB 54828-101: A Phase 1, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies        

IN DEVELOPMENT AND COMING SOON:

Targeted Therapies

OSU-17060: Phase II study of brigatinib for advanced solid cancers harboring genomic alterations in ALK and ROS1 oncogenes

OSU-TBD: A phase II multi-center, single-arm study of oral XXXXX in adult patients with advanced solid tumors of any histology with FGFR1-3 gene fusions or mutations who failed or are intolerant to standard of care therapies.       

Immunotherapies

OSU-TBD: A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors.

Please click on the following link for additional clinical trials at the James, where there are over 500 trials for cancer research:

http://cancer.osu.edu/research-and-education/clinical-research